A new study published in JMIR Dermatology shows that TikTok has become a major source of education and support for people ...

The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension ...

Bimekizumab yields clinically meaningful improvements in the severity of hidradenitis suppurativa over 48 weeks, shifting most patients to a mild disease, a pooled analysis of two trials shows.

Nurse Justus Bell found relief from a painful, often undiagnosed skin disease at a UVA Health clinic, the only one of its ...

Reimbursement authority NICE has said that Incyte's JAK inhibitor cream Opzelura (ruxolitinib) can be used to treat people ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial ...

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that ...

MoonLake Immunotherapeutics shares climbed after the company said a meeting with the Food and Drug Administration had paved the way to file a Biologic License Application for a hidradenitis ...

Factors that affect medical decision-making among patients with hidradenitis suppurativa (HS) include suffering threshold, perceptions of treatment risk, treatment fatigue, understanding of the ...

Sanofi (SNYNF) announced an update on their ongoing clinical study. Study Overview: Sanofi is conducting a Phase 2 clinical trial titled A Randomized, Double-blind, Placebo-controlled, Phase 2, ...